Topics:

Psychosomatic Symptoms in Children With Chronic Medical Illness: Page 2 of 2

Psychosomatic Symptoms in Children With Chronic Medical Illness: Page 2 of 2

Depression

Symptoms of depression and anxiety, such as insomnia, loss of appetite, and fatigue, are common in chronically ill patients and can be overlooked or undertreated. Depressive symptoms add to the burden of illness and have been associated with poorer medical outcomes, treatment nonadherence, repeated hospitalizations, and disease-related complications in medically ill patients.8-11

The prevalence of major depressive disorder and depressive symptoms has been found to be as high as 68% in pediatric patients with serious medical illness.12-14 Most studies use self-rating scales or semi-structured interviews. In evaluating a child or adolescent with depressive symptoms, it is important to distinguish whether the symptoms are attributable to the medical condition and to the effects of treatment or to an underlying psychiatric disorder.

Causes of depression include immune system and cytokine dysfunction, medication complications, endocrine abnormalities or deficien-cies, nutrition-related neurological or medical conditions, and CNS metastases.4 A full medical workup needs to be done to rule out underlying physiological mechanisms before the treatment decision is made.

Focus on the cognitive symptoms of depression, such as poor concentration, low self-esteem, feelings of guilt or of being a burden to others, and any suicidal thoughts (passive or active). Evidence suggests that asking patients, even young children, directly about their suicidal thoughts is the best method to assess suicide risk.15 Medical patients are a vulnerable population at higher risk for suicidal thoughts and behaviors—suicide risk varies by diagnosis, severity of disease, physical functioning, pain management, and prognosis.

When symptoms are attributed to an underlying mood disorder or are causing moderate to severe functional impairment, target antidepressants to specific symptoms. While psychotropic medications have not been studied in medically ill patients in a large-scale systematic manner, one small (N = 15) open-label trial demonstrated that fluvoxamine was well tolerated and significantly improved symptoms of anxiety and depression in pediatric cancer patients.16 Another case report describes citalopram as being well tolerated and effective in treating depression in 4 children with cancer.17

Fluoxetine is an FDA-approved SSRI for depression in children older than 6 years. Fluoxetine, with its active metabolite norfluoxetine, and fluvoxamine are potent inhibitors of cytochrome P-450 (CYP) 3A3 and CYP3A4 and are best avoided, when possible, in combination with macrolide antibiotics, azole antifungal agents, and several other commonly used medications.18

Citalopram has been widely used in medical settings because of its short half-life and low tendency to interact with other drugs.17 However, the recent FDA warning that dosages greater than 40 mg/d can cause QTc prolongation may curb this practice.19 Escitalopram is approved for depression in 12- to 17-year-olds, and amitriptyline is approved for depression in patients aged 12 years or older.

Although difficult to tolerate in high doses because of anticholinergic symptoms and tachycardia, tricyclic antidepressants are often used in low doses to treat insomnia, weight loss, anxiety, and some pain syndromes. Other antidepressants, such as bupropion and duloxetine, have been found to have clinical utility under careful monitoring.

SSRIs and selective noradrenergic reuptake inhibitors are used with caution since the FDA black box warnings about increased risk of suicidal behavior in children and adolescents using these medications. This underscores the need for careful, weekly monitoring of all children treated with antidepressants. In general, it is unusual for medically ill patients to be suicidal without premorbid depression or with adequate pain management.

Anxiety

Pediatric patients with a history of multiple hospitalizations commonly experience anxiety (particularly separation anxiety), procedural anxiety, and adjustment disorders with anxious mood. A number of factors can contribute to the presence of anxiety symptoms: illness-related biological mechanisms, a response to diagnosis or being in the hospital, genetic and psychosocial causes, or a combination of all of these.

Behavioral and cognitive approaches are recommended as first-line treatment for anxiety symptoms. Medical play therapy, cognitive-behavioral therapy, prizes and incentives for procedures, and distraction techniques such as virtual reality and video game interventions, have demonstrated efficacy in ameliorating anxiety symptoms.20-22

For symptoms that persist or become clinically significant, psychopharmacological treatments can be an important adjunct. Benzodiazepines, such as lorazepam, used in low doses in conjunction with nonpharmacological distraction techniques may be appropriate for procedures that provoke significant anxiety in children. Clonazepam, a longer-acting benzodiazepine, may be helpful with more pervasive and prolonged anxiety symptoms.

Benzodiazepines can cause sedation, confusion, and behavioral disinhibition, so their use should be carefully monitored, especially in those with CNS dysfunction. Benzodiazepine withdrawal precipitated by abrupt discontinuation often occurs on transfer out of intensive care settings, so special care should be taken not to discontinue benzodiazepines too abruptly.

In addition, antihistamines are frequently used to sedate anxious children. While diphenhydramine may be helpful for occasional insomnia, antihistamines are not helpful for persistent anxiety, and their anticholinergic properties can precipitate or worsen delirium.

Escitalopram (approved in healthy children older than 12 for depression) and citalopram are used to treat anxiety as well and may lead to fewer drug-drug interactions in medically ill patients.

Summary

Psychopharmacology may supplement psychotherapies such as cognitive-behavioral therapy, behavior work, and family therapy in reducing symptoms of anxiety, depression, and delirium in pediatric medically ill patients—particularly when the disorders are causing significant functional impairment. Left untreated, psychiatric disorders can negatively affect quality of life, symptom management, treatment adherence, medical outcome, and somatic complaints, and they can impede com-pliance with medical procedures. Targeted psychopharmacological treatment, in conjunction with environmental or behavioral interventions, can lessen the severity of mood, sleep, and appetite problems; help medically ill children develop better coping skills surrounding diagnosis, treatment, and procedures; and improve quality of life and functioning in multiple domains.

Pages

References

References

1. Turkel SB, Trzepacz PT, Tavaré CJ. Comparing symptoms of delirium in adults and children. Psychosomatics. 2006;47:320-324.
2. Kurtz BP, Abrams AN. Psychiatric aspects of pediatric cancer. Child Adolesc Psychiatr Clin N Am. 2010;19:401-421, x-xi.
3. Martini DR, Pao M. Psychiatric emergencies. In: Wiener LS, Pao M, Kazak AE, et al, eds. Quick Reference for Pediatric Oncology Clinicians: The Psychiatric and Psychological Dimensions of Pediatric Cancer Symptom Management. Charlottesville, VA: IPOS Press; 2009:121-129.
4. Apter A, Farbstein I, Yaniv I. Psychiatric aspects of pediatric cancer. Child Adolesc Psychiatr Clin N Am. 2003;12:473-492, vii.
5. Karnik NS, Joshi SV, Paterno C, Shaw R. Subtypes of pediatric delirium: a treatment algorithm. Psychosomatics. 2007;48:253-257.
6. Schieveld JN, Leroy PL, van Os J, et al. Pediatric delirium in critical illness: phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit. Intensive Care Med. 2007;33:1033-1040.
7. Munzig E, Turkel S, Jacobson J, et al. Diagnosis and treatment of pediatric delirium. Poster presented at: Academy of Psychosomatic Medicine; November 20, 2008; Miami.
8. de Jonge PD, Hadj FB, Boffa D, et al. Prevention of major depression in complex medically ill patients: preliminary results from a randomized, controlled trial. Psychosomatics. 2009;50:227-233.
9. Koopmans GT, Donker MC, Rutten FH. Length of hospital stay and health service use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry. 2005;27:44-56.
10. Fenton WS, Stover ES. Mood disorders: cardiovascular and diabetes comorbidity. Curr Opin Psychiatry. 2006;19:421-427.
11. Garrison MM, Katon WJ, Richardson LP. The impact of psychiatric comorbidities on readmissions for diabetes in youth. Diabetes Care. 2005;28:2150-2154.
12. Kersun LS, Elia J. Depressive symptoms and SSRI use in pediatric oncology patients. Pediatr Blood Cancer. 2007;49:881-887.
13. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr. 2004;39:395-403.
14. Pao M, Lyon M, D’Angelo LJ, et al. Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. Arch Pediatr Adolesc Med. 2000;154:240-244.
15. Ballard E, Bosk A, Snyder D, et al. Patients’ opinions about suicide screening in a pediatric emergency department. Pediatr Emerg Care. In press.
16. Gothelf D, Rubinstein M, Shemesh E, et al. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry. 2005;44:1258-1262.
17. DeJong M, Fombonne E. Citalopram to treat depression in pediatric oncology. J Child Adolesc Psychopharmacol. 2007;17:371-377.
18. Indiana University School of Medicine, Division of Clinical Pharmacology. P450 Drug Interaction Table. http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed September 28, 2011.
19. US Food and Drug Administration. FDA Drug Safety Communication: Abnormal Heart Rhythms Associated With High Doses of Celexa (Citalopram Hydrobromide). August 2011. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm. Accessed September 28, 2011.
20. Stuber ML, Seacord D. Psychiatric impact of childhood cancer. In: Kreitler S, Ben Arush MW, eds. Psychosocial Aspects of Pediatric Oncology. West Sussex, England: John Wiley & Sons Ltd; 2004:211-228.
21. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, et al. Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol. 1997;65:366-380.
22. Patel A, Schieble T, Davidson M, et al. Distraction with a hand-held video game reduces pediatric preoperative anxiety. Paediatr Anaesth. 2006;16:1019-1027.
23. US Food and Drug Administration. FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed October 7, 2011.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.